Related Experiment Video

Updated: Nov 5, 2025

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.2K

NT5DC2 promotes leiomyosarcoma tumour cell growth via stabilizing unpalmitoylated TEAD4 and generating a positive

Bowen Hu1, Shijie Zhou2, Xuefeng Hu3

  • 1Department of Orthopedics, Orthopedics Research Institute, West China Hospital, Sichuan University, Chengdu, China.

Journal of Cellular and Molecular Medicine
|May 16, 2021
PubMed

Insights

5'-Nucleotidase Domain Containing 2 (NT5DC2) is upregulated in leiomyosarcoma (LMS), promoting cancer growth by stabilizing TEAD4. Inhibiting this NT5DC2-TEAD4 loop offers a potential therapeutic strategy for LMS.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • 5'-Nucleotidase Domain Containing 2 (NT5DC2) is a novel oncoprotein with poorly understood regulatory functions.
  • Leiomyosarcoma (LMS) is a challenging cancer where novel therapeutic targets are needed.

Purpose of the Study:

  • To investigate the expression, regulation, and function of NT5DC2 in LMS.
  • To explore the interplay between NT5DC2 and TEAD4 in LMS pathogenesis.

Main Methods:

  • Bioinformatic analysis using TCGA and GTEx data.
  • In vitro and in vivo studies using LMS cell lines (SK-LMS-1, SK-UT-1).
  • Analysis of protein interactions, ubiquitination, cell cycle, proliferation, and gene transcription.

Main Results:

  • NT5DC2 is aberrantly upregulated in LMS and associated with poor survival.
  • NT5DC2 deletion suppressed LMS cell proliferation by inducing G1 phase arrest and reducing cell cycle gene expression.
  • NT5DC2 stabilized unpalmitoylated TEAD4 by inhibiting its proteasomal degradation, while TEAD4 activated NT5DC2 transcription, forming a positive feedback loop.

Conclusions:

  • The NT5DC2-TEAD4 positive feedback loop is crucial for LMS development.
  • Targeting the NT5DC2-TEAD4 axis presents a potential therapeutic strategy for leiomyosarcoma.
Keywords:
NT5DC2TEAD4leiomyosarcomaubiquitin-proteasome pathway

More Related Videos

Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics08:11

Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics

Published on: March 26, 2018

8.5K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

406

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.8K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.2K